Pete Strong

Pete is Pulmocide’s Chief Scientific Officer. Pete’s pharmaceutical industry career between 1980 and 2003 was spent at Glaxo, GlaxoWellcome and GlaxoSmithKline with a focus on respiratory drug discovery and development. Pete co-founded Respivert with Garth Rapeport and colleagues in 2007. Following the acquisition in 2010 by Centocor Ortho Biotech, Pete was a member of the small team which licensed the appropriate Respivert intellectual property rights to Topivert Ltd, leading to the successful Series A funding of that company. With Garth and colleagues, Pete then co-founded Pulmocide Ltd. in 2013.